Nyxoah publishes positive clinical data - Gilde Healthcare

Nyxoah publishes positive clinical data

28 oktober 2019

Utrecht (The Netherlands) and Mont-Saint-Guibert (Belgium) – Nyxoah S.A., a healthtech company focused on the development of innovative solutions and services for sleep related disorders, announced today the publication of data from the BLAST OSA (BiLAteral Hypoglossal Nerve Stimulation for Treatment of Obstructive Sleep Apnea) clinical study for the Genio® system in the European Respiratory Journal. These data demonstrate that treatment with the Genio® system was safe and effective, and resulted in significant improvement in patients’ Quality of Life measurements.

Key results from the BLAST OSA study include a significant reduction in OSA severity both in terms of Apnea Hypopnea Index (AHI) and Oxygen Desaturation Index (ODI); a significant improvement of daytime sleepiness; and sleep-related quality of life. The number of bed partners reporting loud, very intense snoring, or leaving the bedroom due to participant snoring decreased from 96% to 35% while 91% of participants reported using the device more than 5 days per week.

The Genio® system is the world’s first and only battery-free, leadless and minimally invasive neurostimulator, capable of delivering bilateral hypoglossal nerve stimulation in moderate to severe Obstructive Sleep Apnea (OSA) patients who have not tolerated, have failed or refused Positive Airway Pressure (PAP) therapy.

 

About Nyxoah
Nyxoah is a healthtech company focused on the development of innovative, neurostimulation-based solutions and services for sleep related disorders. Nyxoah’s lead technology is the Genio® system, the world’s first and only, battery-free, leadless and minimally invasive implanted neurostimulator that treats the underlying cause of Obstructive Sleep Apnea (OSA), a market worth approximately $10bn in the US alone. The Genio® system received its European CE Mark in March 2019 and a US trial programme for FDA approval is in preparation.
Nyxoah was co-founded in 2009 by Robert Taub, a renowned entrepreneur and serial investor in the life sciences sector. Since its inception, the Company has raised over €50m from M. Taub and private investors, Gilde Healthcare, a high quality, healthcare specialist international investor, SRIW, the Regional Investment Company of Wallonia and Cochlear, an international medical device company which develops a range of implantable hearing solutions. For more information, visit the company’s website at www.nyxoah.com.
 
About Gilde Healthcare
Gilde Healthcare is a specialized European healthcare investor managing € 1 billion ($ 1.2 billion) across two fund strategies: venture & growth capital and private equity. Gilde Healthcare’s venture & growth capital fund invests in health tech and therapeutics. The venture & growth companies are based in Europe and North America. Gilde Healthcare’s private equity fund invests in profitable European lower mid-market healthcare companies with a focus on the Benelux and DACH region. The private equity fund targets healthcare providers, suppliers of medical products and service providers in the healthcare market. For more information, visit the company’s website at www.gildehealthcare.com.

Gilde Healthcare portfolio company Eetgemak joins forces with TotaalVERS to become the leading integrated healthcare foodservice provider

Combining TotaalVERS and Eetgemak will form a leading end-to-end foodservice provider*, offering a wide range of convenience meals, ingredients and groceries to the healthcare sector. The partnership emphasizes commitment to quality, service, and innovation in...
5 juli 2024

Gilde Healthcare company Volta Medical announces positive results from transatlantic trial on AI-assisted ablation for persistent atrial fibrillation

TAILORED-AF randomized controlled trial (RCT) findings demonstrated superiority in freedom from atrial fibrillation (AF) at 12 months from a tailored cardiac ablation guided by artificial intelligence (AI) when compared to pulmonary vein isolation (PVI) alone....
21 mei 2024

Gilde Healthcare co-leads $100M equity financing in Karius

Karius®, Inc., a world leader in genomic diagnostics for infectious disease, today announced it has secured $100 million in Series C funding. The round was co-led by Gilde Healthcare, Khosla Ventures and 5AM Ventures, and...
2 mei 2024